Ganfeng Cao 曹敢峰

Ganfeng Cao has extensive work experience in the field of process chemistry and CMC. Ganfeng is currently serving as the Vice President and Head of Process Chemistry, CMC at Prelude Therapeutics since March 2023. Prior to their current role, they held positions such as Executive Director and Head of Process Chemistry, CMC at Prelude Therapeutics from April 2021 to March 2023, Senior Director and Head of Process Chemistry, CMC from April 2020 to April 2021, and Director, CMC from August 2018 to April 2020. Before joining Prelude Therapeutics, Ganfeng Cao worked as the CSO for Biotech assets acquisition at Big Apple Medical Group/US/Shenzhen from May 2017 to July 2018. Ganfeng also had a long tenure at Incyte, where they served as SR PI from August 2009 to May 2017, PI Medicinal Chemistry from January 2003 to August 2009, and PI (role duration not specified).

Ganfeng Cao completed their Bachelor of Science (BS) degree in Medicinal and Pharmaceutical Chemistry at Beijing Medical University (Peking U, School of Pharmaceutical Sciences) from 1988 to 1992. Following this, they pursued a Master of Science (MS) degree in Medicinal and Pharmaceutical Chemistry from 1992 to 1995 at Peking Union Medical College. Later, Cao furthered their education by attending the University of Michigan, where they obtained a Ph.D. in Organic Chemistry from 1998 to 2003.